Lead Product(s): LM-030
Therapeutic Area: Dermatology
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 14, 2020
LM-030 is the only program in clinical development for Netherton and could potentially become the first approved targeted therapy.